The purpose of this study was to demonstrate the bioequivalence of Deflox® 50 milligrams (mg)
tablets compared with Cataflam® DD tablets 50 mg administered as single dose in fasting
conditions to healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany